

Fig. 1


Neg
5D8
h5D8
p-STAT3
STAT3
β-actin

Fig. 2A


r5D8
h5D8
0
62.5
62.5
31.25
6.25
0.62
nM
p-STAT3
STAT3
β-actin

Fig. 2B


MSD Signal
3000
2000
1000
0
-2
-1
0
1
2
3
h5D8 [log nM]

Fig. 3A


U251 pSTAT3
Normalized MSD Signal
IC50 0.78
0.004
0.003
0.002
0.001
0.000
-3
-2
-1
0
1
2
3
h5D8 [log nM]
U251 pSTAT3
Normalized MSD Signal
IC50 1.4
r5D8 [log nM]

Fig. 3B



Fig. 4


GBM
NSCLC
Ovarian
CRC
Pancreatic
LIF H-score
300
200
100
0
Low LIF
High LIF

Fig. 5


Tumor volume
(30 days post-surgery)
p<0.05
p<0.05
6×10⁶
4×10⁶
2×10⁶
0
-2×10⁶
Total flux (p/s)
Vehicle
h5D8
15 mg/kg
h5D8
30 mg/kg

Fig. 6A


8×10⁶
6×10⁶
4×10⁶
2×10⁶
0
Flux
5
10
15
Time
control
r5D8

Fig. 6B


* (p=0.02)
2.0×10 10
1.5×10 10
1.0×10 10
5.0×10 09
0
Total Flux [p/s]
vehicle
r5D8

Fig. 7A


p=0.08
* (p=0.02)
** (p=0.002)
2.5✖10 8
2.0✖10 8
1.5✖10 8
1.0✖10 8
5.0✖10 7
0
Total flux (p/s)
Vehicle
100 µg
200 µg
300 µg

Fig. 7B



Fig. 8A



Fig. 8B



Fig. 8C


1500
1000
500
0
tumor volume (mm3)
vehicle
r5D8
10
15
20
Days

Fig. 9A


***
2500
2000
1500
1000
500
0
tumor size (mm3)
vehicle
r5D8

Fig. 9B


CCL22
IBA-1
MERGE DAPI
vehicle
r5D8
*** (p=0.0002)
% CCL22+ / IBA1+ cells
100
80
60
40
20
0
vehicle
r5D8

Fig. 10A


MRC1
IBA-1
MERGE DAPI
Control
h5D8
CCL22
IBA-1
MERGE DAPI
Control
h5D8

Fig. 10B



Fig. 10C



Fig. 10D


Vehicle
M2
9.16
Mnull
61.4
M1
19.1
h5D8
M2
0.50
Mnull
43.3
M1
46.9
CD11b
% in CD45
control
h5D8
TAM
% in CD45
control
h5D8
M1: CD206neg/MHCIIhigh
% in TAM
control
h5D8
M2: CD206high/MHCIIneg
% in TAM
control
h5D8

Fig. 10E



Fig. 10F


Immune cell
% CD45+
control
r5D8
Thelper CD4+ cell
% CD3+ CD4+
control
r5D8
Tcytotoxic CD8+ cell
% CD3+ CD8+
control
r5D8
NK cell
% CD3- CD49b+
control
r5D8
Activated Thelper CD4+ cell
% CD4+ CD69+
control
r5D8
Activated Tcytotoxic CD8+ cell
% CD8+ CD69+
control
r5D8

Fig. 11A


%CD3+,CD49b+
** (p=0.009)
control
r5D8
%CD3+,CD4+
p=0.33
control
r5D8
%CD3+,CD8+
* (p=0.026)
control
r5D8

Fig. 11B


vehicle
r5D8
26.41%
17.72%
CD25
FoxP3
% CD4+ Tregs
30
20
10
0
p=0.15
vehicle
r5D8

Fig. 11C


ns (p=0.06)
**** (p<0.0001)
** (p=0.003)
* (p=0.01)
tumor size (mm3)
1000
500
0
Control
r5D8
aCD4+aCD8
aCD4+aCD8+ r5D8

Fig. 12



Fig. 13A



Fig. 13B



Fig. 14A



Fig. 14B



Fig. 15A



Fig. 15B



Fig. 16A



Fig. 16B



Fig. 16C


Mean Expression:
Adipose - mesenteric
Blood vessel – choroid-plexus (brain)
Blood vessel – mesenteric (colon)
Umbilical-cord
1000.0
100.0
10.0
1.0
Brain: Cortex (temporal)
Brain: substantia-nigra
copies/100ng Total RNA
Mean n=3 per tissue

Fig. 17A


Mean Expression:
Adipose - mesenteric
Blood vessel - pulmonary
Thyroid
Neural
PBMC
10000.0
1000.0
100.0
10.0
1.0
copies/100ng Total RNA
Mean n=3 per tissue

Fig. 17B


h5D8 / Cisplatin combo / CT26 SC
Vehicle
Control IgG1
h5D8
Cisplatin
h5D8 + Cis
Tumor volume (mm^3)
1000
500
0
0
5
10
15
20
Time (days)
vehicle
p=0.0083
control IgG
h5D8 or cisplatin
p=0.037
h5D8+cisplatin

Fig. 18



Fig. 19A



Fig. 19B


h5D8 / Cisplatin combo / CT26 ID
Control IgG
h5D8
Cisplatin
Combo
Tumor volume (mm^3)
600
400
200
0
0
5
10
15
20
25
Day
control IgG
p=0.0045
h5D8
cisplatin
p=0.012
h5D8+cisplatin

Fig. 20